Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

Completed · Phase 2

Conditions studied: Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma

In brief

This study will determine the overall response rate and toxicity of rituximab and Velcade in combination in patients with relapsed or refractory mantle cell non-Hodgkin's lymphoma.

Key facts

Study ID

NCT00201877

Run by

Ohio State University Comprehensive Cancer Center

People needed

25

Starts

2004-12-01

Expected to finish

2012-03-01

Last updated by the study team

2018-03-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed mantle cell or follicular lymphoma
• Relapsed or refractory disease
• ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, 2 or 3

You may not qualify if…

• Pre-existing sensory or motor peripheral neuropathy
• No active or untreated CNS (Central Nervous System) lymphoma
• History of severe, life-threatening hypersensitivity or infusion reactions prior rituximab treatment.

Where it is running

• Ohio State University Medical Center — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.